Kubota Pharmaceutical Holdings Co., Ltd. (TYO:4596)
Japan · Delayed Price · Currency is JPY 69.00
-1.00 (-1.43%)
Aug 27, 2026, 1:12 PM JST
TYO:4596 Income Statement
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 16 | 21 | 27 | 39 | 8 | - | |
Revenue Growth | -46.67% | -22.22% | -30.77% | 387.50% | -78.38% | - |
Cost of Revenue | 44 | 26 | 5 | 12 | 5 | - |
Gross Profit | -28 | -5 | 22 | 27 | 3 | - |
Selling, General & Admin | 570 | 543 | 711 | 633 | 602 | 604 |
Research & Development | 480 | 310 | 543 | 788 | 1,512 | 2,040 |
Other Operating Expenses | -19 | - | 1 | 110 | - | - |
Operating Expenses | 1,031 | 853 | 1,255 | 1,531 | 2,114 | 2,644 |
Operating Income | -1,059 | -858 | -1,233 | -1,504 | -2,111 | -2,644 |
Interest Expense | - | - | -7 | -9 | -11 | -18 |
Interest & Investment Income | 2 | 1 | 5 | 13 | 18 | 11 |
Other Non Operating Income (Expenses) | 217 | 217 | 15 | 11 | 89 | 35 |
EBT Excluding Unusual Items | -840 | -640 | -1,220 | -1,489 | -2,015 | -2,616 |
Gain (Loss) on Sale of Assets | - | - | -56 | - | - | - |
Asset Writedown | -36 | -36 | -56 | - | - | - |
Pretax Income | -876 | -676 | -1,332 | -1,489 | -2,015 | -2,616 |
Net Income | -876 | -676 | -1,332 | -1,489 | -2,015 | -2,616 |
Net Income to Common | -876 | -676 | -1,332 | -1,489 | -2,015 | -2,616 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 102 | 64 | 56 | 56 | 49 | 46 |
Shares Outstanding (Diluted) | 102 | 64 | 56 | 56 | 49 | 46 |
Shares Change | 77.09% | 13.32% | 1.35% | 12.85% | 8.19% | 6.30% |
EPS (Basic) | -8.62 | -10.59 | -23.64 | -26.78 | -40.90 | -57.45 |
EPS (Diluted) | -8.62 | -10.59 | -23.65 | -26.79 | -40.92 | -57.46 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -729 | -593 | -1,244 | -1,401 | -2,143 | -2,521 |
Free Cash Flow Per Share | -7.17 | -9.29 | -22.08 | -25.20 | -43.50 | -55.36 |
Gross Margin | -175.00% | -23.81% | 81.48% | 69.23% | 37.50% | - |
Operating Margin | -6618.75% | -4085.71% | -4566.67% | -3856.41% | -26387.50% | - |
Profit Margin | -5475.00% | -3219.05% | -4933.33% | -3817.95% | -25187.50% | - |
Free Cash Flow Margin | -4556.25% | -2823.81% | -4607.41% | -3592.31% | -26787.50% | - |
EBITDA | - | -793 | -1,168 | -1,417 | -2,053 | -2,585 |
D&A For EBITDA | - | 65 | 65 | 87 | 58 | 59 |
EBIT | -1,059 | -858 | -1,233 | -1,504 | -2,111 | -2,644 |